Cancer Family
Peripheral Nervous System Neoplasm
CI-CAN-00000316Explore in graph →
Non-malignant71 active trials8 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000316Explore in graph →
Clinical trials
261 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00924196 | Natural History Study of Patients With Neurofibromatosis Type I | active not recruiting | — | 259 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01362803 | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | active not recruiting | Phase 1 / Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06175637 | Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs(PEDIA) | active not recruiting | — | 409 | AstraZenecaINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04394858 | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer | active not recruiting | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04590235 | A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | active not recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT03962543 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas(ReNeu) | active not recruiting | Phase 2 | 114 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03541720 | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | active not recruiting | Early Phase 1 | 13 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03363217 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | active not recruiting | Phase 2 | 114 | St. Justine's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04040088 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04924608 | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas(KOMET) | active not recruiting | Phase 3 | 145 | AstraZenecaINDUSTRY | 13 | Mar 23, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03839498 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | active not recruiting | Phase 2 | 6 | Columbia UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03946527 | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)(LAMPARA) | active not recruiting | Phase 2 | 10 | Antonio FojoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05581511 | Natural History Study of Cutaneous Neurofibromas in People With NF1(cNF Natural Hx) | active not recruiting | — | 500 | Johns Hopkins UniversityOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05233878 | Prognostic's Factors of Head and Neck Paragangliomas Evolution(PRONO-PARAG) | active not recruiting | — | 25 | Hospices Civils de LyonOTHER | 1 | Jun 30, 2025 | clinicaltrials |
| NCT05913037 | FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | active not recruiting | Phase 3 | 167 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04954001 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | active not recruiting | Phase 1 / Phase 2 | 160 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 3 | Nov 12, 2024 | clinicaltrials |
| NCT05446779 | Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death(SuddenDeath) | active not recruiting | — | 400 | Helsinki University Central HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03820778 | Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | active not recruiting | N/A | 10 | Children's National Research InstituteOTHER | 1 | Mar 2, 2021 | clinicaltrials |
Data updated 10 hours agoSource updated Sep 29, 2026source: clinicaltrials